Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06450197




Registration number
NCT06450197
Ethics application status
Date submitted
8/05/2024
Date registered
10/06/2024
Date last updated
21/10/2024

Titles & IDs
Public title
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
Scientific title
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease
Secondary ID [1] 0 0
D9690C00005
Universal Trial Number (UTN)
Trial acronym
AMALTHEA
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Moderate to Severe Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AZD7798
Other interventions - Placebo

Experimental: AZD7798 - AZD7798

Placebo comparator: Placebo - Placebo


Treatment: Drugs: AZD7798
AZD7798

Other interventions: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
CDAI remission
Timepoint [1] 0 0
Week 12
Secondary outcome [1] 0 0
Endoscopic response
Timepoint [1] 0 0
Week 12
Secondary outcome [2] 0 0
Endoscopic remission
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Endoscopic score change from baseline
Timepoint [3] 0 0
Week 12
Secondary outcome [4] 0 0
CDAI response
Timepoint [4] 0 0
Week 12
Secondary outcome [5] 0 0
CDAI score change from baseline
Timepoint [5] 0 0
Week 12
Secondary outcome [6] 0 0
Symptomatic remission
Timepoint [6] 0 0
Week 12
Secondary outcome [7] 0 0
Serum AZD7798 concentration
Timepoint [7] 0 0
Up to 85 days
Secondary outcome [8] 0 0
Incidence of anti-drug antibody response
Timepoint [8] 0 0
Up to 36 weeks
Secondary outcome [9] 0 0
Titre of anti-drug antibody response
Timepoint [9] 0 0
Up to 36 weeks

Eligibility
Key inclusion criteria
1. 18 to 80 years of age.
2. Diagnosis of Crohn's disease established with verifiable clinical, imaging, endoscopic and/or histopathologic evidence.
3. Moderate to severe active Crohn's disease.
4. Ileal/ileocecal (L1), colonic (L2), or ileocolonic (L3) disease, as classified based on the localisation of active inflammation.
5. Capable of giving signed informed consent.
6. A history of at least one of:

1. Intolerance or inadequate response to conventional treatment (oral corticosteroid, azathioprine, 6-mercaptopurine, or methotrexate), biologics, or other approved advanced therapy (eg, JAK inhibitors) OR
2. Corticosteroid dependency (defined as inability to taper below budesonide 6 mg/day or prednisolone 10 mg/day without recurrent active disease) for the treatment of Crohn's disease.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Evidence, or clinical suspicion, of other forms of IBD or concomitant additional active gastrointestinal luminal inflammatory diseases.
2. Known symptomatic strictures or bowel stenoses or strictures preventing passage of endoscope throughout the colon.
3. Any complications of Crohn's disease where surgery is anticipated or planned prior to end of study treatment.
4. Evidence of extensive prior gastrointestinal surgical interventions.
5. Within 3 months prior to screening endoscopy visit:

1. History of toxic megacolon
2. Diagnosis of peritonitis or need for treatment of peritonitis
3. Bowel perforation or evidence of obstruction.
6. Undrained fistula or abscess, including intrabdominal abscesses.
7. Ongoing or expected nutritional dependency on total enteral or parenteral nutrition during study.
8. Evidence of an increased risk of colorectal cancer.
9. Symptomatic oral Crohn's disease within one year.
10. Any of the following treatments within the specified time period prior to screening endoscopy visit

1. An anti-TNF biologic within 8 weeks prior to screening endoscopy visit
2. Any biologic targeting immune response other than an anti-TNF within 12 weeks prior to screening endoscopy visit
3. Other advanced small molecule treatments for Crohn's disease within 4 weeks prior to screening endoscopy visit
4. Cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, or tacrolimus (FK-506) within 4 weeks prior to screening endoscopy visit
5. Treatment with apheresis within 4 weeks prior to screening endoscopy visit
6. Administration of any live vaccine within 4 weeks prior to screening endoscopy visit to end of study
7. Faecal microbiota transplantation within 4 weeks prior to screening endoscopy visit
8. Lymphocyte-depleting treatment within 12 months prior to screening endoscopy visit
9. Any previous exposure to AZD7798.
11. Any changes in dosing of the following medications prior to screening endoscopy visit as outlined:

1. 5-aminosalicylates within 2 weeks
2. Oral corticosteroids within 2 weeks:

(i) Prednisolone (ii) Budesonide (c) Immunomodulators within 4 weeks (d) Antibiotic therapy for the treatment of Crohn's disease (e) Probiotics within 2 weeks.
12. Known or suspected history of chronic use of nonsteroidal anti-inflammatory drugs.
13. Evidence of recent or currently active infection, including use of IV or oral antibiotics for documented infection within 30 days prior to screening endoscopy visit.
14. Evidence of chronic HBV or HCV.
15. History of TB (active or latent) unless an appropriate course of treatment has been completed.
16. Positive diagnostic TB test at screening.
17. History of serious opportunistic infection within 12 months prior to screening endoscopy visit.
18. CMV colitis within previous 12 months prior to screening endoscopy visit.
19. Positive C. difficile toxin stool test at screening.
20. Symptomatic herpes zoster infection within 3 months prior to screening endoscopy.
21. Any identified immunodeficiency.
22. Abnormal laboratory results at screening suggesting participation may be unsafe, which will prevent the patient from completing the study, or will interfere with the interpretation of the study results.
23. Reproduction:

1. Pregnant and breastfeeding patients, or those planning to breastfeed during the study
2. FOCBP unless completely abstinent or using a highly effective contraception and barrier method of contraception.
24. Prolonged QTcF interval.
25. Clinically significant cardiovascular conditions.
26. Current malignancy or history of malignancy.
27. Current significant major or unstable respiratory disease, heart disease, cerebrovascular disease, haematological disease, hepatic disease, renal disease, gastrointestinal disease or other major disease other than active Crohn's disease.
28. Current enrolment in another interventional study or treatment with any investigational drug within 4 months prior to screening endoscopy visit.
29. Unstable lifestyle factors.
30. Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/08/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
21/05/2027
Actual
Sample size
Target
192
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Adelaide
Recruitment hospital [2] 0 0
Research Site - Bedford Park
Recruitment hospital [3] 0 0
Research Site - Box Hill
Recruitment hospital [4] 0 0
Research Site - Epping
Recruitment hospital [5] 0 0
Research Site - Fitzroy
Recruitment hospital [6] 0 0
Research Site - Heidelberg
Recruitment hospital [7] 0 0
Research Site - Liverpool
Recruitment hospital [8] 0 0
Research Site - Melbourne
Recruitment hospital [9] 0 0
Research Site - Parkville
Recruitment hospital [10] 0 0
Research Site - South Brisbane
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
3128 - Box Hill
Recruitment postcode(s) [4] 0 0
3076 - Epping
Recruitment postcode(s) [5] 0 0
3065 - Fitzroy
Recruitment postcode(s) [6] 0 0
3084 - Heidelberg
Recruitment postcode(s) [7] 0 0
2170 - Liverpool
Recruitment postcode(s) [8] 0 0
3004 - Melbourne
Recruitment postcode(s) [9] 0 0
3050 - Parkville
Recruitment postcode(s) [10] 0 0
QLD 4101 - South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Kansas
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
North Carolina
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
Argentina
State/province [13] 0 0
Buenos Aires
Country [14] 0 0
Argentina
State/province [14] 0 0
Caba
Country [15] 0 0
Argentina
State/province [15] 0 0
Ciudad Autonoma de Bs As
Country [16] 0 0
Argentina
State/province [16] 0 0
Ciudad Autonoma de Buenos Aires
Country [17] 0 0
Argentina
State/province [17] 0 0
Quilmes
Country [18] 0 0
Argentina
State/province [18] 0 0
San Miguel de Tucumán
Country [19] 0 0
Austria
State/province [19] 0 0
Klagenfurt
Country [20] 0 0
Austria
State/province [20] 0 0
Wien
Country [21] 0 0
Belgium
State/province [21] 0 0
Aalst
Country [22] 0 0
Belgium
State/province [22] 0 0
Gent
Country [23] 0 0
Belgium
State/province [23] 0 0
Leuven
Country [24] 0 0
Belgium
State/province [24] 0 0
Liège
Country [25] 0 0
Brazil
State/province [25] 0 0
Campinas
Country [26] 0 0
Brazil
State/province [26] 0 0
Curitiba
Country [27] 0 0
Brazil
State/province [27] 0 0
Jaú
Country [28] 0 0
Brazil
State/province [28] 0 0
Porto Alegre
Country [29] 0 0
Brazil
State/province [29] 0 0
Santo Andre
Country [30] 0 0
Brazil
State/province [30] 0 0
São Paulo
Country [31] 0 0
Bulgaria
State/province [31] 0 0
Gorna Oryahovitsa
Country [32] 0 0
Bulgaria
State/province [32] 0 0
Plovdiv
Country [33] 0 0
Bulgaria
State/province [33] 0 0
Sofia
Country [34] 0 0
Canada
State/province [34] 0 0
Alberta
Country [35] 0 0
Canada
State/province [35] 0 0
Ontario
Country [36] 0 0
Chile
State/province [36] 0 0
Santiago
Country [37] 0 0
Chile
State/province [37] 0 0
Talcahuano
Country [38] 0 0
Chile
State/province [38] 0 0
Viña del Mar
Country [39] 0 0
China
State/province [39] 0 0
Chengdu
Country [40] 0 0
China
State/province [40] 0 0
Guangzhou
Country [41] 0 0
China
State/province [41] 0 0
Nanchang
Country [42] 0 0
China
State/province [42] 0 0
Nanjing
Country [43] 0 0
China
State/province [43] 0 0
Wuhan
Country [44] 0 0
Croatia
State/province [44] 0 0
Osijek
Country [45] 0 0
Croatia
State/province [45] 0 0
Rijeka
Country [46] 0 0
Croatia
State/province [46] 0 0
Zagreb
Country [47] 0 0
France
State/province [47] 0 0
Amiens Cedex 1
Country [48] 0 0
France
State/province [48] 0 0
Lille
Country [49] 0 0
France
State/province [49] 0 0
Montpellier Cedex 5
Country [50] 0 0
France
State/province [50] 0 0
Pierre Benite
Country [51] 0 0
France
State/province [51] 0 0
Vandoeuvre-Les-Nancy
Country [52] 0 0
Germany
State/province [52] 0 0
Berlin
Country [53] 0 0
Germany
State/province [53] 0 0
Frankfurt
Country [54] 0 0
Germany
State/province [54] 0 0
Halle
Country [55] 0 0
Germany
State/province [55] 0 0
Kiel
Country [56] 0 0
Germany
State/province [56] 0 0
Ulm
Country [57] 0 0
Hungary
State/province [57] 0 0
Bekescsaba
Country [58] 0 0
Hungary
State/province [58] 0 0
Budapest
Country [59] 0 0
Hungary
State/province [59] 0 0
Gyöngyös
Country [60] 0 0
Italy
State/province [60] 0 0
Firenze
Country [61] 0 0
Italy
State/province [61] 0 0
Milano
Country [62] 0 0
Italy
State/province [62] 0 0
Roma
Country [63] 0 0
Italy
State/province [63] 0 0
Rome
Country [64] 0 0
Japan
State/province [64] 0 0
Chiba-shi
Country [65] 0 0
Japan
State/province [65] 0 0
Hamamatsu-shi
Country [66] 0 0
Japan
State/province [66] 0 0
Hiroshima-shi
Country [67] 0 0
Japan
State/province [67] 0 0
Kamakura-shi
Country [68] 0 0
Japan
State/province [68] 0 0
Kashiwa-shi
Country [69] 0 0
Japan
State/province [69] 0 0
Kure-shi
Country [70] 0 0
Japan
State/province [70] 0 0
Minato-ku
Country [71] 0 0
Japan
State/province [71] 0 0
Morioka
Country [72] 0 0
Japan
State/province [72] 0 0
Nagoya-shi
Country [73] 0 0
Japan
State/province [73] 0 0
Osaka-shi
Country [74] 0 0
Japan
State/province [74] 0 0
Sakura-shi
Country [75] 0 0
Japan
State/province [75] 0 0
Shinjuku-ku
Country [76] 0 0
Malaysia
State/province [76] 0 0
Johor Bahru
Country [77] 0 0
Malaysia
State/province [77] 0 0
Kota Bharu
Country [78] 0 0
Malaysia
State/province [78] 0 0
Kota Kinabalu
Country [79] 0 0
Malaysia
State/province [79] 0 0
Kuala Lumpur
Country [80] 0 0
Malaysia
State/province [80] 0 0
Kuching
Country [81] 0 0
Mexico
State/province [81] 0 0
Durango
Country [82] 0 0
Mexico
State/province [82] 0 0
Merida
Country [83] 0 0
Mexico
State/province [83] 0 0
Mexico City
Country [84] 0 0
Mexico
State/province [84] 0 0
Mexico
Country [85] 0 0
Mexico
State/province [85] 0 0
Tlajomulco de Zuniga
Country [86] 0 0
Mexico
State/province [86] 0 0
Veracruz
Country [87] 0 0
Netherlands
State/province [87] 0 0
Amsterdam
Country [88] 0 0
Netherlands
State/province [88] 0 0
Nijmegen
Country [89] 0 0
Netherlands
State/province [89] 0 0
Tilburg
Country [90] 0 0
Poland
State/province [90] 0 0
Bydgoszcz
Country [91] 0 0
Poland
State/province [91] 0 0
Chojnice
Country [92] 0 0
Poland
State/province [92] 0 0
Krakow
Country [93] 0 0
Poland
State/province [93] 0 0
Kraków
Country [94] 0 0
Poland
State/province [94] 0 0
Lublin
Country [95] 0 0
Poland
State/province [95] 0 0
Poznan
Country [96] 0 0
Poland
State/province [96] 0 0
Sopot
Country [97] 0 0
Poland
State/province [97] 0 0
Warszawa
Country [98] 0 0
Poland
State/province [98] 0 0
Wroclaw
Country [99] 0 0
Romania
State/province [99] 0 0
Bucharest
Country [100] 0 0
Romania
State/province [100] 0 0
Bucuresti
Country [101] 0 0
Romania
State/province [101] 0 0
Cluj Napoca
Country [102] 0 0
Romania
State/province [102] 0 0
Timisoara
Country [103] 0 0
Slovakia
State/province [103] 0 0
Kosice
Country [104] 0 0
Slovakia
State/province [104] 0 0
Nitra
Country [105] 0 0
Slovakia
State/province [105] 0 0
Presov
Country [106] 0 0
Slovakia
State/province [106] 0 0
Trnava
Country [107] 0 0
South Africa
State/province [107] 0 0
Assagay
Country [108] 0 0
South Africa
State/province [108] 0 0
Cape Town
Country [109] 0 0
South Africa
State/province [109] 0 0
Milnerton
Country [110] 0 0
South Africa
State/province [110] 0 0
Plumstead
Country [111] 0 0
Spain
State/province [111] 0 0
Barcelona
Country [112] 0 0
Spain
State/province [112] 0 0
Las Palmas de Gran Canaria
Country [113] 0 0
Spain
State/province [113] 0 0
Madrid
Country [114] 0 0
Spain
State/province [114] 0 0
Sevilla
Country [115] 0 0
Sweden
State/province [115] 0 0
Linköping
Country [116] 0 0
Sweden
State/province [116] 0 0
Stockholm
Country [117] 0 0
Taiwan
State/province [117] 0 0
Kaohsiung
Country [118] 0 0
Taiwan
State/province [118] 0 0
New Taipei City
Country [119] 0 0
Taiwan
State/province [119] 0 0
Taichung
Country [120] 0 0
Taiwan
State/province [120] 0 0
Taipei
Country [121] 0 0
Taiwan
State/province [121] 0 0
Taoyuan
Country [122] 0 0
Turkey
State/province [122] 0 0
Ankara
Country [123] 0 0
Turkey
State/province [123] 0 0
Antalya
Country [124] 0 0
Turkey
State/province [124] 0 0
Bursa
Country [125] 0 0
Turkey
State/province [125] 0 0
Istanbul
Country [126] 0 0
Turkey
State/province [126] 0 0
Izmir
Country [127] 0 0
Turkey
State/province [127] 0 0
Izmit
Country [128] 0 0
Turkey
State/province [128] 0 0
Malatya
Country [129] 0 0
Ukraine
State/province [129] 0 0
Chernivts?
Country [130] 0 0
Ukraine
State/province [130] 0 0
Kiev
Country [131] 0 0
Ukraine
State/province [131] 0 0
Kyiv
Country [132] 0 0
Ukraine
State/province [132] 0 0
Ternopil
Country [133] 0 0
Ukraine
State/province [133] 0 0
Vinnytsia
Country [134] 0 0
Vietnam
State/province [134] 0 0
Hanoi
Country [135] 0 0
Vietnam
State/province [135] 0 0
Ho Chi Minh city
Country [136] 0 0
Vietnam
State/province [136] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
Trial website
https://clinicaltrials.gov/study/NCT06450197
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
AstraZeneca Clinical Study Information Center
Address 0 0
Country 0 0
Phone 0 0
1-877-240-9479
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06450197